Google+

Biotech Companies

 

ADEPTRIXC81a- Rev. png

 

 

 

 

Advastim

 

 

 

 

 

 

 

 

 

 

Cell Assay Innovations

 

 

 

 

Epathochhem Logo 1.2

 

 

 

 

 

InsomniSolv-Logo_FinalColor

 

 

 

 

lariat_final

 

 

 

 

 

Quad Logo

 

 

 

 

 

RANBiotech Logo

 

 

 

 

 

 

Seqwell logo. jpg

 

 

 

 

TBS_logoDesign_05_CMYK

 

 

 

 

 

 

TrBio_Color

 

 

 

 

Adeptrix   www.adeptrix.com

Developing the next generation of bead-based bioassays, which employ mass spectrometry and optical imaging to facilitate high information content proteomic research.

Vladislav Bergo, CEO  

 

AdvaStim   www.advastim.com

Developing advanced neuorostimulation products and neuromodulation technologies that reduce device failure rates and improved efficacy over time.

Larry Derose, CEO;  Barry Yomtov, CTO

 

Cellanyx Diagnostics LLC  www.cellanyx.com

Developing in vitro tissue and cell culturing techniques for use in research and in vitro diagnostics, specifically prognostic information for prostate cancer treatment decisions.

Ashok Chander,CEO; Mani Foroohar,CSO

 

Cell Assay Innovations, Inc.   www.cellassayinnov.com

A biotechnology service company dedicated to cell-based assay technology development with a focus on proprietary kinase assay panels for drug screening and other cell culture services.

Deborah Moshinsky, President; LiPing Wu, CSO

 

HepatoChem   www.hepatochem.com

Offers pharmaceutical and biotech companies reliable and efficient access to small molecule metabolites in order to accelerate drug R&D and reduce costs.

Marc Bazin, President; Ryan Buzdygon, Director of Operations

 

InSomniSolv www.angel.co/insomnisolv 

Developing a neurostimulator device to mitigate insomnia.

Peter Kelley, Founder; John Douglas, Consultant

 

Lariat Biosciences   www.lariatbiosciences.com

Developing a non‐invasive diagnostic to detect early signs of cancer based on circulating DNA fragments arising from the death of tumor cells which carry the mutant genetic signature that gave rise to the abnormal growth.

Jonathan Larson, CEO

 

Quad Technologies, LLCwww.quadtechnologies.net

Has a game changing dissolvable hydrogel technology, QuickGel™ that can selectively bind antibodies, proteins, or cells from solution while mitigating non-specific binding. QuickGel™ has applications in label-free cell separation, offline-sample prep, and IVD.

Sean Kevlahan, CEO; Brian Plouffe, CSO; Jeffrey Zonderman, COO

 

RAN Biotechnologies, Inc.   www.ranbiotechnologies.com

Designs and manufacture two types of materials: (1) Solid Resins for selective capture and controlled release of viruses, bacteria, and proteins. Examples of related applications are viral clearance, vaccine purification, fluid disinfection and diagnostics; (2) FluoroSurfactants for droplet microfluidics.

Roger Nassar, CEO

 

seqWell, Inc. www.seqwell.com

Offers a DNA sequencing service called kiloSEQ ™, based on novel and proprietary technology that will enable high-quality, long-read sequencing of plasmids and amplicons for development of therapeutic biologicals and synthetic biology applications.

Joseph Mellor, CEO; Jack Leonard, Head of Operations

 

Thrive Bioscience, Inc. www.thrivebio.com

Is developing Smart Incubation Systems™ that will automatically monitor, maintain, passage, and assay cell and tissue culture.

Gary Magnant, CEO; Alan Blanchard, CSO; Thomas Farb, COO/CFO; Brian Foley, VP of Engineering & Manufacturing

 

Tribiotica www.tribiotica.com

TriBiotica’s proprietary technology uses the tumor’s unique genetic signature to force the tumor cells to assemble novel immune targets that would not be naturally produced, but which allows specific elimination of tumor cells

Jim Kurnick, MD, Chairman; Matt Lawlor, President; Ian Dunn, CTO; Estelle Newton